リキッドバイオプシー市場：製品別（アッセイキット、機器、サービス）、循環バイオマーカー別（CTC、ctDNA）、技術別（NGS、PCR）、用途別（がん（肺、乳房、前立腺）、非がん）、エンドユーザー別（リファレンスラボ、病院） - 2026年までの世界予測

Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026

世界のリキッドバイオプシー市場は、2021年の25億米ドルから2026年には58億米ドルに達すると予測されており、予測期間中のCAGRは18.1%となっています。市場の成長は、がんの発症率や有病率の上昇、非侵襲的な治療... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2021年11月30日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	225	202	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のリキッドバイオプシー市場は、2021年の25億米ドルから2026年には58億米ドルに達すると予測されており、予測期間中のCAGRは18.1%となっています。市場の成長は、がんの発症率や有病率の上昇、非侵襲的な治療法への関心の高まりなどの要因によってもたらされます。一方で、特定のリキッドバイオプシーの感度が低いことが、この市場の成長を抑制する要因となる可能性があります。
"液体生検市場の製品・サービス別では、予測期間中、アッセイキット分野が最も高い成長率を示した"
リキッドバイオプシー市場は、製品・サービス別に、アッセイキット、機器、サービスに分かれています。2020年、リキッドバイオプシー市場では、アッセイキットセグメントが最も高い成長率を示しました。幅広い種類の試薬やキットが利用できること、多様なアッセイへのアクセスが容易であること、がんの罹患率が上昇していることなどが、リキッドバイオプシーのアッセイキット市場の成長を促進する主な要因となっています。
"Non-cancer applicationssegment accounted for the highest CAGR"
アプリケーションに基づいて、液体バイオプシー市場は、がんアプリケーションと非がんアプリケーションに分けられます。2020年には、非がんアプリケーションのセグメントが最も高い成長率を占めました。これは、NIPTや臓器移植診断の研究活動が活発化していることに起因すると考えられます。
"アジア太平洋地域。急成長する地域液体バイオ市場"
世界の液体バイオ市場は、北米、欧州、アジア太平洋地域、その他の地域に分けられます。予測期間中、アジア太平洋地域が最も高いCAGRを記録すると予測されています。
疾病の早期発見や定期的な健康診断に対する意識向上を目的とした政府の取り組み、継続的な医療費の増加、インドや中国における病院や臨床診断研究所の数の増加、インド、中国、日本における診断法の研究基盤の強化などの要因が、市場の成長を後押しすると予想されます。さらに、政府の支援的な規制は、予測期間中の市場の成長をさらに促進するでしょう。

本レポートのために行われた主要なインタビューは、以下のように分類されます。

- 企業タイプ別。企業タイプ別：ティア1-40％、ティア2-30％、ティア3-30％。
- 呼称別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米51％、欧州21％、アジア太平洋地域18％、中南米6％、中東・アフリカ4％。
レポートに掲載されている企業の一覧です。

- F. ホフマン・ラ・ロシュ社（スイス(スイス)
- Myriad Genetics, Inc.(米国)
- QIAGEN N.V. (オランダ)
- テルモフィッシャーサイエンティフィック社（米国(米国)
- Guardant Health, Inc.(米国)
- MDxHealth SA（ベルギー）
- エグザクト・サイエンス・コーポレーション（米国）
- Illumina Inc.(米国)
- Sysmex Inostics（シスメックス・インスティテュート）（米国
- Bio-Rad Laboratories, Inc.(米国)
- Biocept, Inc.(米国)
- NeoGenomics, Inc.(米国)
- ANGLE plc（英国）
- Menarini-Silicon Biosystems（イタリア）
- Vortex Biosciences, Inc.(米国)
- Exosome Diagnostics, Inc.(米国)
- アジェナ・バイオサイエンス社（米国(米国)
- MedGenome Inc.(米国)
- エピゲノミクスAG（ドイツ）
- Personal Genome Diagnostics, Inc.(米国)
調査対象
当レポートでは、世界の液体バイオ市場の詳細を明らかにしています。製品・サービス、臨床アプリケーション、技術、循環バイオマーカー、アプリケーション、エンドユーザーなどの異なるセグメントにおける市場規模と今後の成長性を推定することを目的としています。また、主要な市場参加者の会社概要、最近の動向、主要な市場戦略など、詳細な競合分析も行っています。

このレポートを購入する主なメリット
本レポートは、リキッドバイオプシー市場全体とそのサブセグメントの収益数値の最も近い近似値を提供することで、市場リーダーや新規参入者を支援します。また、ステークホルダーが競合状況をよりよく理解し、ビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得ることができます。本レポートは、ステークホルダーが市場の脈動を理解し、主要な市場ドライバー、阻害要因、機会、および課題に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.2.2 MARKETS COVERED 31
FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION 31
1.2.3 YEARS CONSIDERED FOR THE STUDY 32
1.3 CURRENCY 32
1.4 LIMITATIONS 32
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.2 RESEARCH APPROACH 35
FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN 35
2.2.1 SECONDARY DATA 36
2.2.1.1 Key data from secondary sources 36
2.2.2 PRIMARY DATA 37
2.2.2.1 Primary sources 37
2.2.2.2 Key data from primary sources 38
2.2.2.3 Key industry insights 39
2.2.2.4 Breakdown of primary interviews 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET) 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.3 MARKET SIZE ESTIMATION 40
2.3.1 BOTTOM-UP APPROACH 41
2.3.1.1 Approach 1: Company revenue estimation approach 41
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 41
2.3.1.2 Approach 2: Presentations of companies and primary interviews 41
2.3.1.3 Growth forecast (2021-2026) 42
2.3.1.4 CAGR projections 42
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
2.3.2 TOP-DOWN APPROACH 42
FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 43

2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 44
2.5 MARKET SHARE 45
2.6 ASSUMPTIONS FOR THE STUDY 45
2.7 LIMITATIONS 46
2.8 RISK ASSESSMENT 46
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET 46
2.9 GROWTH RATE ASSUMPTIONS 47
2.10 COVID-19 HEALTH ASSESSMENT 47
2.11 COVID-19 ECONOMIC ASSESSMENT 47
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 47
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 48
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 49
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET 50
3 EXECUTIVE SUMMARY 51
FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 51
FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2021 VS. 2026 (USD MILLION) 52
FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 52
FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 53
FIGURE 15 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2021 VS. 2026 (USD MILLION) 53
FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 54
FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 55
4 PREMIUM INSIGHTS 56
4.1 LIQUID BIOPSY MARKET OVERVIEW 56
FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET 56
4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 57
FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE
THE MARKET IN 2026 57
4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 57
FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 57
4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026 58
FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 58
4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026 58
FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 58
4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026 59
FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 59
4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026 59
FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 59
4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 62
5.2.1.1 Rising incidence and prevalence of cancer 62
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020,
BY TYPE OF CANCER 62
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations 63
5.2.1.3 Increasing preference for noninvasive treatment procedures 63
5.2.2 RESTRAINTS 64
5.2.2.1 The lower sensitivity of certain liquid biopsies 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 The growing significance of companion diagnostics 65
5.2.3.2 Growth opportunities in emerging countries 65
5.2.4 CHALLENGES 66
5.2.4.1 Unclear reimbursement scenario 66
5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET 66
5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS 67
5.4.1 LIQUID BIOPSY MARKET 67
FIGURE 27 REALISTIC SCENARIO 67
FIGURE 28 PESSIMISTIC SCENARIO 68
FIGURE 29 OPTIMISTIC SCENARIO 68
5.5 PRICING ANALYSIS 69
TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021) 69
5.6 PATENT ANALYSIS 70
5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS 70
5.7 VALUE CHAIN ANALYSIS 71
FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 71
FIGURE 31 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 72
5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET 73
FIGURE 32 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 73
5.9 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 3 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 73
5.9.1 THREAT OF NEW ENTRANTS 74
5.9.2 THREAT OF SUBSTITUTES 74
5.9.3 BARGAINING POWER OF BUYERS 74
5.9.4 BARGAINING POWER OF SUPPLIERS 74
5.9.5 DEGREE OF COMPETITION 74
5.10 REGULATORY LANDSCAPE 74
5.10.1 NORTH AMERICA 74
5.10.1.1 US 74
5.10.1.2 Canada 75
5.10.2 EUROPE 75
5.10.3 ASIA PACIFIC 75
5.10.3.1 China 75
5.10.3.2 Japan 75
5.10.4 LATIN AMERICA 75
5.10.4.1 Brazil 76
5.10.4.2 Mexico 76
5.10.5 MIDDLE EAST 76
5.10.6 AFRICA 76
5.11 TECHNOLOGY ANALYSIS 77
5.12 PESTLE ANALYSIS 78
5.13 TRADE ANALYSIS 79
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 79
5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million) 79
5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons) 79
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 79
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS 79
5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET 80
6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
TABLE 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 82
6.2 ASSAY KITS 82
6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT 82
TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET 83
TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION,
2019–2026 (USD MILLION) 83

6.3 INSTRUMENTS 84
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT 84
TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET 85
TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION) 85
6.4 SERVICES 85
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH 85
TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY REGION,
2019–2026 (USD MILLION) 86
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS 87
7.1 INTRODUCTION 88
7.1.1 PRIMARY NOTES 88
7.1.1.1 Key industry insights 88
TABLE 10 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 88
7.2 CIRCULATING TUMOR CELLS (CTC) 89
7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT 89
TABLE 11 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019–2026 (USD MILLION) 89
7.3 CIRCULATING TUMOR DNA (CTDNA) 90
7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER 90
TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION,
2019–2026 (USD MILLION) 90
7.4 CELL-FREE DNA (CFDNA) 91
7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 91
TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION,
2019–2026 (USD MILLION) 91
7.5 EXTRACELLULAR VESICLES (EVS) 91
7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT 91
TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION,
2019–2026 (USD MILLION) 92
7.6 OTHER CIRCULATING BIOMARKERS 92
TABLE 15 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019–2026 (USD MILLION) 93

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 94
8.1 INTRODUCTION 95
8.1.1 PRIMARY NOTES 95
8.1.1.1 Key industry insights 95
TABLE 16 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 95
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 95
8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE
THE GROWTH OF THIS SEGMENT 95
TABLE 17 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019–2026 (USD MILLION) 96
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS 96
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT 96
TABLE 18 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019–2026 (USD MILLION) 96
9 LIQUID BIOPSY MARKET, BY APPLICATION 97
9.1 INTRODUCTION 98
TABLE 19 LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 98
9.2 CANCER APPLICATIONS 98
TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION) 99
TABLE 21 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION,
2019–2026 (USD MILLION) 99
TABLE 22 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2019–2026 (USD MILLION) 100
9.2.1 LUNG CANCER 100
9.2.1.1 Increasing prevalence of lung cancer to propel the market growth 100
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 101
TABLE 24 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 101
9.2.2 BREAST CANCER 102
9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth 102
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 103
9.2.3 COLORECTAL CANCER 103
9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth 103
TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 104
TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION,
2019–2026 (USD MILLION) 104
9.2.4 PROSTATE CANCER 105
9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market 105
TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
TABLE 30 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION,
2019–2026 (USD MILLION) 106
9.2.5 MELANOMA 106
9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth 106
TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 107
TABLE 32 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION,
2019–2026 (USD MILLION) 107
9.2.6 OTHER CANCERS 107
TABLE 33 GLOBAL CANCER INCIDENCE, 2020 108
TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION) 108
9.3 NON-CANCER APPLICATIONS 108
9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT 108
TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 109
10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 110
10.1 INTRODUCTION 111
TABLE 36 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 111
10.2 THERAPY SELECTION 111
10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT 111
TABLE 37 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION,
2019–2026 (USD MILLION) 112
10.3 TREATMENT MONITORING 112
10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS 112
TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION,
2019–2026 (USD MILLION) 113
10.4 RECURRENCE MONITORING 113
10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 113
TABLE 39 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019–2026 (USD MILLION) 114
10.5 EARLY CANCER SCREENING 114
10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH 114
TABLE 40 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019–2026 (USD MILLION) 115

11 LIQUID BIOPSY MARKET, BY END USER 116
11.1 INTRODUCTION 117
TABLE 41 LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 117
11.2 REFERENCE LABORATORIES 117
11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT 117
TABLE 42 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 118
11.3 HOSPITALS AND PHYSICIAN LABORATORIES 118
11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT 118
TABLE 43 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 119
11.4 ACADEMIC & RESEARCH CENTERS 119
11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT 119
TABLE 44 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019–2026 (USD MILLION) 120
11.5 OTHER END USERS 120
TABLE 45 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION) 120
12 LIQUID BIOPSY MARKET, BY REGION 121
12.1 INTRODUCTION 122
TABLE 46 LIQUID BIOPSY MARKET, BY REGION, 2019–2026 (USD MILLION) 122
12.2 NORTH AMERICA 122
TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020,
BY TYPE OF CANCER 123
FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 124
TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 125
TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION) 125
TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 125
TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 126
TABLE 53 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION) 126
TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 126
12.2.1 US 127
12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US 127
TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 127
TABLE 56 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 128
TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 128
TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 128
TABLE 59 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 129
TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 129
12.2.2 CANADA 129
12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada 129
TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 130
TABLE 62 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 130
TABLE 63 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 131
TABLE 64 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 65 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 132
12.3 EUROPE 132
TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 133
TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 133
TABLE 69 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 133
TABLE 70 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 134
TABLE 71 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 72 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 135
12.3.1 GERMANY 135
12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany 135
TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 136
TABLE 75 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 136
TABLE 76 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 136
TABLE 77 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 78 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 137
12.3.2 UK 138
12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth 138
TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 138
TABLE 81 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 139
TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 139
TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 139
TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 140
TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 140
12.3.3 FRANCE 140
12.3.3.1 Rising R&D expenditure in France to drive the market growth 140
TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 141
TABLE 87 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 141
TABLE 88 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 141
TABLE 89 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 90 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 142
12.3.4 REST OF EUROPE 143
TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 143
TABLE 93 ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 143
TABLE 94 ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 144
TABLE 95 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 144
TABLE 96 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 145
12.4 ASIA PACIFIC 145
FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT 146
TABLE 98 APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146
TABLE 99 APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 147
TABLE 100 APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 147
TABLE 101 APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 147
TABLE 102 APAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 103 APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 148
12.4.1 CHINA 149
12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China 149
TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 149
TABLE 106 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 149
TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 150
TABLE 108 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 151
12.4.2 JAPAN 151
12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan 151
TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 151
TABLE 112 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 152
TABLE 113 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 152
TABLE 114 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 115 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 153
TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 153
12.4.3 INDIA 153
12.4.3.1 Increasing private & public investments in the country’s healthcare system is expected to drive the market growth 153
TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 154
TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 154
TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 155
TABLE 120 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 121 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 156
12.4.4 REST OF ASIA PACIFIC 156
TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 156
TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 157
TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 157
TABLE 126 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 157
TABLE 127 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 158
12.5 REST OF THE WORLD 158
TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 159
TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 159
TABLE 131 ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 159
TABLE 132 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 160
TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 160
13 COMPETITIVE LANDSCAPE 161
13.1 OVERVIEW 161
13.2 KEY PLAYER STRATEGIES 161
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
THE LIQUID BIOPSY MARKET 161
TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES 161
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 163
FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN
THE LIQUID BIOPSY MARKET 163
13.4 MARKET SHARE ANALYSIS 164
FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020) 164
TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION 164
13.5 COMPANY EVALUATION QUADRANT 165
13.5.1 LIST OF EVALUATED VENDORS 165
13.5.2 STARS 165
13.5.3 EMERGING LEADERS 166
13.5.4 PERVASIVE PLAYERS 166
13.5.5 PARTICIPANTS 166
FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 166
13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020) 167
13.6.1 PROGRESSIVE COMPANIES 167
13.6.2 STARTING BLOCKS 167
13.6.3 RESPONSIVE COMPANIES 167
13.6.4 DYNAMIC COMPANIES 167
FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020 168
13.7 COMPETITIVE BENCHMARKING 168
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET 168
TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT 169
TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT 169
13.8 COMPETITIVE SCENARIO 170
13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS 170
TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 170
13.8.2 DEALS 171
TABLE 140 KEY DEALS 171
13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS 172
TABLE 141 OTHER KEY DEVELOPMENTS 172
14 COMPANY PROFILES 173
14.1 KEY PLAYERS 173
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 QIAGEN N.V. 173
TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW 173
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 174
14.1.2 F. HOFFMANN-LA ROCHE 177
TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 177
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 178
14.1.3 MYRIAD GENETICS, INC. 180
TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW 180
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020) 181
14.1.4 THERMO FISHER SCIENTIFIC INC. 184
TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 184
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 185
14.1.5 GUARDANT HEALTH, INC. 188
TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 188
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020) 189
14.1.6 BIO-RAD LABORATORIES 192
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 192
FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 193
14.1.7 ILLUMINA, INC. 195
TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW 195
FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020) 196
14.1.8 EXACT SCIENCES 198
TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW 198
FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020) 199
14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION) 201
TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW 201
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 201
14.1.10 BIOCEPT, INC. 203
TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW 203
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020) 203
14.1.11 MDX HEALTH 207
TABLE 152 MDX HEALTH: BUSINESS OVERVIEW 207
FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020) 207
14.2 OTHER PLAYERS 209
14.2.1 NEOGENOMICS, INC. 209
14.2.2 ANGLE PLC 211
14.2.3 EPIGENOMICS AG 212
14.2.4 MENARINI-SILICON BIOSYSTEMS 213
14.2.5 VORTEX BIOSCIENCES, INC. 214
14.2.6 EXOSOME DIAGNOSTICS, INC. 215
14.2.7 MEDGENOME INC. 216
14.2.8 AGENA BIOSCIENCE, INC. 217
14.2.9 PERSONAL GENOME DIAGNOSTICS, INC. 219
14.2.10 FREENOME HOLDINGS, INC. 221
14.2.11 STRAND LIFE SCIENCES 222
14.2.12 LUNGLIFE AI, INC. 222
14.2.13 LUCENE HEALTH INC. 223
14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 224
15.1 DISCUSSION GUIDE 224
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 228
15.3 AVAILABLE CUSTOMIZATIONS 230
15.4 RELATED REPORTS 230
15.5 AUTHOR DETAILS 231

ページTOPに戻る

Table of Contents

Summary

The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% during the forecast period. Market growth is driven by factors such as the rising incidence & prevalence of cancerand the increasing preference for noninvasive treatment procedures. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.
“The assay kits segment accounted for the highest growth rate in theliquid biopsy market, by product& service, during the forecast period”
The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. In 2020, the assay kits segment accounted for the highest growth rate in the liquid biopsy market. The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are the major factors driving the growth of the liquid biopsy assay kits market.
“Non-cancer applicationssegment accounted for the highest CAGR”
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2020, the non-cancer application segment accounted for the highest growth rate. This can be attributed to the increasing research activities in NIPT and organ transplant diagnosis.
“Asia Pacific: The fastest-growing regionliquid biopsymarket”
The global liquid biopsymarket is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japanare expected to boost the market growth. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Myriad Genetics, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Thermo Fisher Scientific, Inc. (US)
• Guardant Health, Inc. (US)
• MDxHealth SA (Belgium)
• Exact Sciences Corporation (US)
• Illumina Inc. (US)
• Sysmex Inostics (US)
• Bio-Rad Laboratories, Inc. (US)
• Biocept, Inc. (US)
• NeoGenomics, Inc. (US)
• ANGLE plc (UK)
• Menarini-Silicon Biosystems (Italy)
• Vortex Biosciences, Inc. (US)
• Exosome Diagnostics, Inc. (US)
• Agena Bioscience, Inc. (US)
• MedGenome Inc. (US)
• Epigenomics AG (Germany)
• Personal Genome Diagnostics, Inc. (US)
Research Coverage:
This report provides a detailed picture of the global liquid biopsymarket. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, clinical application, technology, circulating biomarkers, application, and end user. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, andchallenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（assay）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（assay）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?